ArticleNature communications2025
Targeting lipid raft-related stomatin to ameliorate osteoporosis in preclinical models.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- KLF6 regulates osteoclastogenesis through DUSP16 in OVX-induced bone loss.Science China. Life sciences · 2026Article
- Stomatin encapsulates aquaporin-1 and urea transporter-B in the erythrocyte membrane.Science advances · 2026Article
- Pearl-Like Bioinspired Coating Enables Regulation of Mg Degradation for Osteoporotic Bone Repair.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Wilforine attenuates inflammatory osteolysis by suppressing osteoclast fusion through JAK-STAT-stomatin immunoregulatory signaling.Frontiers in immunology · 2026Article
- Neutrophil extracellular traps drive osteoporosis via NCF2-dependent signaling: integrated transcriptomics with mechanistic validation.Redox report : communications in free radical research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Osteoporosis is a metabolic bone disease characterized by a disruption in the balance between bone resorption and formation. The specific role and mechanism of stomatin (STOM), a major component of lipid rafts, in regulating bone physiology remain unclear. This research identifies increased STOM expression in bone tissue of osteoporosis patients and ovariectomized mice. STOM-deficient mice show higher bone mass under both normal conditions and after ovariectomy. Furthermore, we clarify that STOM is a positive regulator of osteoclast differentiation. Through transcriptomic and bioinformatics approaches, our research reveals that inhibiting STOM increases antioxidant proteins and suppresses ROS-mediated transcriptional pathways in osteoclasts. Mechanistically, STOM interacts with Prdx1, promoting its degradation through the lysosomal pathway and boosting intracellular ROS production, thereby activating osteoclastogenesis. Ultimately, targeted inhibition of macrophage STOM expression in mice alleviates ovariectomized-induced bone loss. Overall, these findings show STOM directly regulates osteoclasts, suggesting that targeting it may modulate pathological bone remodeling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.